March 30, 2021 5:49pm

Just another rotation, rebalance, cycle, circumvolution, a plain old shift or a recognition for being oversold

Pre-open indication results: 6 HITs and 1 MISS

News: Intellia Therapeutics (NTLA +$6.93) the European Commission (EC) has granted orphan drug designation to NTLA-2001; being developed as a treatment for transthyretin amyloidosis (ATTR), a rare condition that can impact a number of organs and tissues within the body through the accumulation of misfolded transthyretin (TTR) protein deposits.

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence

Numbers based facts speak better then opinion as I see answers in numbers that equate to facts!

The Dow closed DOWN – 104.41 points (-0.31%); the S&P closed DOWN -12.54 points (-0.32%) while the Nasdaq closed DOWN -14.25 points (-0.11%)



Indexes fell Tuesday under pressure again after the 10-year Treasury yield touched its highest level (to top +1.77 and then fall to +1.72%%) since January 2020.

The Nasdaq was on track for its first monthly loss since November following the recent rise in yields.

The market and the cell and gene therapy have been experienced heightened volatility this week but, to “our” universe today; amid the continued fallout after a hedge fund was forced to liquidate its position in several media stocks. <CNBC>

A plus, the Russell 2000 value index was up 0.1%, outperforming the Russell 2000 growth index, which shed about 0.6% in a continuation of a trend since late last year.


Data Docket: Investors digested a reading on consumer confidence that far exceeded expectations. The Conference Board’s Consumer Confidence Index surged in March to 109.7, its highest reading in a year. Economists polled by Dow Jones expected the index to rise to 96.8 from 90.4 in February.


RegMed Investors’ (RMi) pre-open: “countdown – 2 sessions and the month/quarter closes   


Pre-open indication results:  6 HITs <Maintain SELL: Biostage (BSTG -$0.125 with 758 shares): BUY: Editas Medicine (EDIT +$0.79), Verastem (VSTM +$0.00), uniQure NV (QURE +$3.12), Sangamo Therapeutics (SGMO +$0.08); SELL: bluebird bio (BLUE -$2.32) and 1 MISS < Intellia Therapeutics (NTLA +$6.93)>


RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions

  • Tuesday opened negative at 4/29, 1 flat and 1 acquired, strayed positive at the mid-day to 24/10 and 1 acquired, closing positive at 23/9, 2 flat and 1 acquired;


There are clear winners and losers

Jumping with share pricing momentum: 

  • Intellia Therapeutics (NTLA), ReNeuron (RENE.L), Ultragenyx (RARE), CRISPR Therapeutics (CRSP), uniQure NV (QURE) to name 5 of the 5 inclining of the 35 covered

Hammered in today’s market:

  • bluebird bio (BLUE), Cellectis SA (CLLS), Ionis Pharmaceuticals (IONS), Bellicum Pharmaceuticals (BLCM), Mesoblast (MESO), Biostage (BSTG), Solid Biosciences (SLDB), Precigen (PGEN), Regenxbio (RGNX) to name 9 of the 9 declining of the 35 covered


Key metrics:

  • Sector volume had LOW with 6 of the 24-upside having higher than the 3-month average volume with the volume of 0 of 9-downside having higher than the 3-month average volume;
  • Tuesday’s percentage (%) of the 24-upside were +0.21% (ADVM) to +10.61% (NTLA) while the 9-downside ranges from -0.12% (RGNX) to -8.33% (BSTG);


Tuesday’s (10 of 24) incline

  • Intellia Therapeutics (NTLA +$6.93 after Monday’s +$0.58);
  • ReNeuron (RENE.L +$6.50 after Monday’s +$2.00);
  • Ultragenyx (RARE +$3.12 after Monday’s -$1.74);
  • CRISPR Therapeutics (CRSP +$4.48 after Monday’s -$0.52);
  • uniQure NV (QURE +$3.12 after Monday’s +$0.93);
  • Sage Therapeutics (SAGE +$1.68 after Monday’s -$2.14);
  • Vericel (VCEL +$1.59 after Monday’s -$0.59);
  • Alnylam Pharmaceuticals (ALNY +$1.33 after Monday’s -$2.45);
  • Fate Therapeutics (FATE +$1.32 after Monday’s +$0.61),
  • Chinook Therapeutics (KDNY +$1.09 after Monday’s -$1.08);

Tuesday’s (9 of 9) decliners:

  • bluebird bio (BLUE -$2.32 after Monday’s +$0.96);
  • Cellectis SA (CLLS -$0.29);
  • Mesoblast (MESO -$0.29);
  • Ionis Pharmaceuticals (IONS -$0,25 after Monday's +$2.01);
  • Bellicum Pharmaceuticals (BLCM -$0.23);
  • Biostage (BSTG -$0.125);
  • Solid Biosciences (SLDB -$0.07);
  • Precigen (PGEN -$0.07 after Monday’s -$0.68);
  • Regenxbio (RGNX -$0.04 after Monday’s -$0.84);

Closing: 2 – Verastem (VSTM), Voyager Therapeutics (VYGR) and 1 - Stemline Therapeutics (STML – acquired)


Sentiment and COVID-19 infections:

  • Total vaccinations – 146 M.

Infection cases <Million>: never to forget …

  • Tuesday 30.85 M cases,
  • Tuesday’s death rate totaled 546,704 <Johns Hopkins University>



The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB closed down -0.39% and XBI closed up +0.58%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was down -1.13 points or -5.45% at 19.61

Upside volume: low

  • Tuesday: 6 out of the 24-upside had higher than the 3-month average volume;

Downside volume: low

  • Tuesday: 0 out of the 9-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: % and pricing drop

  • Tuesday’s percentage (%) of the 24-upside were +0.21% (ADVM) to +10.61% (NTLA) while the 9-downside ranges from -0.12% (RGNX) to -8.33% (BSTG);

March, the 3rd month of Q1/21:

Tuesday closed positive with 25 advancers, 9 decliners, 2 flats and 1 acquired


The BOTTOM LINE: We were on the winning side of trading today … Wild swings have hit the market and could deepen (later this week) when pension funds and other big investors conduct their quarter-end rebalancing.

Who says, one can’t make it as a retail investor … trade it to make it!

“Again, my time horizon for HOLDING an equity is last Friday through Thursday (this week)” – think about that and check the Advance/Decline (A/D line) to VALIDATE my thesis.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.